» Articles » PMID: 26452630

International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society Consensus Statements for Screening and Treating Depression and Anxiety

Overview
Journal Thorax
Date 2015 Oct 11
PMID 26452630
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

Studies measuring psychological distress in individuals with cystic fibrosis (CF) have found high rates of both depression and anxiety. Psychological symptoms in both individuals with CF and parent caregivers have been associated with decreased lung function, lower body mass index, worse adherence, worse health-related quality of life, more frequent hospitalisations and increased healthcare costs. To identify and treat depression and anxiety in CF, the CF Foundation and the European CF Society invited a panel of experts, including physicians, psychologists, psychiatrists, nurses, social workers, a pharmacist, parents and an individual with CF, to develop consensus recommendations for clinical care. Over 18 months, this 22-member committee was divided into four workgroups: Screening; Psychological Interventions; Pharmacological Treatments and Implementation and Future Research, and used the Population, Intervention, Comparison, Outcome methodology to develop questions for literature search and review. Searches were conducted in PubMed, PsychINFO, ScienceDirect, Google Scholar, Psychiatry online and ABDATA by a methodologist at Dartmouth. The committee reviewed 344 articles, drafted statements and set an 80% acceptance for each recommendation statement as a consensus threshold prior to an anonymous voting process. Fifteen guideline recommendation statements for screening and treatment of depression and anxiety in individuals with CF and parent caregivers were finalised by vote. As these recommendations are implemented in CF centres internationally, the process of dissemination, implementation and resource provision should be closely monitored to assess barriers and concerns, validity and use.

Citing Articles

Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis.

Uzunoglu B, Selcuk Balci M, Kalyoncu M, Karabulut S, Metin Cakar N, Yildiz C Pediatr Pulmonol. 2025; 60(3):e71037.

PMID: 40062574 PMC: 11892081. DOI: 10.1002/ppul.71037.


Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients.

Garcia M, Pelaez A, Punter R, Lopez M, Carbajal C, Ancochea J BMC Pulm Med. 2025; 25(1):81.

PMID: 39962495 PMC: 11831831. DOI: 10.1186/s12890-024-03455-2.


Psychosocial and mental health in cystic fibrosis in the modern era of care: time to evolve.

Harrigan M, Georgiopoulos A, Quittner A, Smith B, Douglas T BMJ Open Respir Res. 2025; 12(1).

PMID: 39929550 PMC: 11815457. DOI: 10.1136/bmjresp-2024-002606.


Increasing and maintaining rates of standardized depression screening in youth with childhood-onset systemic lupus erythematosus in a pediatric rheumatology clinic.

Datyner E, Dingle J, Newsome V, Buckley L, Belsky N, Park S Pediatr Rheumatol Online J. 2025; 23(1):3.

PMID: 39754107 PMC: 11699778. DOI: 10.1186/s12969-024-01038-3.


The prevalence and implications of depression and anxiety in patients with bronchiectasis: a systematic review and meta-analysis.

Chang M, Kim H, Lee J ERJ Open Res. 2024; 10(6).

PMID: 39655172 PMC: 11626616. DOI: 10.1183/23120541.00248-2024.


References
1.
Felger J, Lotrich F . Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013; 246:199-229. PMC: 3741070. DOI: 10.1016/j.neuroscience.2013.04.060. View

2.
Birnie K, Noel M, Chambers C, Uman L, Parker J . Psychological interventions for needle-related procedural pain and distress in children and adolescents. Cochrane Database Syst Rev. 2018; 10:CD005179. PMC: 6517234. DOI: 10.1002/14651858.CD005179.pub4. View

3.
Havermans T, Colpaert K, Dupont L . Quality of life in patients with Cystic Fibrosis: association with anxiety and depression. J Cyst Fibros. 2008; 7(6):581-4. DOI: 10.1016/j.jcf.2008.05.010. View

4.
. Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force Recommendation Statement. Pediatrics. 2009; 123(4):1223-8. DOI: 10.1542/peds.2008-2381. View

5.
Sawicki G, Sellers D, Robinson W . High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2008; 8(2):91-6. PMC: 2680350. DOI: 10.1016/j.jcf.2008.09.007. View